Atyr Pharma Faces Nasdaq Delisting Notice

TL;DR

Nasdaq's coming for Atyr Pharma's listing, stock might get booted.

AI Summary

Atyr Pharma, Inc. announced on December 4, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options and plans to respond to the notice.

Why It Matters

This notice suggests Atyr Pharma may be delisted from the Nasdaq, which could significantly impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Receiving a delisting notice from a major stock exchange like Nasdaq poses a significant risk to the company's continued trading and investor perception.

Key Players & Entities

• Atyr Pharma, Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Exchange issuing notice
• December 4, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M
• $1.00 — Company's common stock had closed below $1.00 per share, the minimum closing bid pric

Filing Documents

• atyr-20251204.htm (8-K) — 50KB
• 0001193125-25-309619.txt ( ) — 157KB
• atyr-20251204.xsd (EX-101.SCH) — 27KB
• atyr-20251204_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 4, 2025, aTyr Pharma, Inc. (the "Company") received a deficiency notice (the "Notice") from the listing qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until June 2, 2026 (the "Compliance Date") to regain compliance with the minimum bid price requirement by having shares of the Company's common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date. If the Company's common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance. To qualify for the second compliance period, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that t

View Full Filing

View this 8-K filing on SEC EDGAR